Tvardi reports 2025 net loss $18.2M; cash to fund into Q4 2026; key clinical milestones ahead

Tvardi Therapeutics, Inc.

2026-Q1 EPS reported -$0.73

Net loss for 2025 was $18.2M ($2.46 basic EPS); cash $30.8M expected to fund operations into Q4 2026.
R&D expenses decreased to $18.0M in 2025 from $23.7M in 2024, driven by lower TTI-101 clinical costs.
Phase 2 IPF trial of TTI-101 showed 9.4% fibrosis reduction vs 2.4% placebo; IL-6 declined 4.5-fold.
Topline data from TTI-109 healthy volunteer study expected Q2 2026; TTI-101 HCC Phase 2 data in H2 2026.
G&A expenses rose to $8.7M in 2025 from $4.5M in 2024 due to merger-related professional fees.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tvardi Therapeutics, Inc. reported the fourth quarter and full-year ended December 31, 2025 results: net income Net loss for the three months ended December 31, 2025, was $7.3 million...For the full year 2025, net loss was $18.2 mil, EPS Basic and diluted net loss per share...for the three months ended December 31, 2025, were a net loss of $(0.78) on a bas.

Period: the fourth quarter and full-year ended December 31, 2025
Net income: Net loss for the three months ended December 31, 2025, was $7.3 million...For the full year 2025, net loss was $18.2 mil
EPS: Basic and diluted net loss per share...for the three months ended December 31, 2025, were a net loss of $(0.78) on a bas
Result: reported results

Exact text from the filing

On March 31, 2026, Tvardi Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the fiscal quarter and year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-037724

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.